WOBURN, Mass.–(BUSINESS WIRE)–SeqLL, LLC today announced the launch of the tSMS System Early Access Program giving researchers priority access to its proprietary quantitative sequencing platform. This benchtop system has been designed to deliver unparalleled quantitative RNA and specialty DNA sequencing results to both academic and industry research partners. tSMS has the capacity to detect low-fold changes and discover rare transcripts that are missed by other sequencing methods and address challenging samples such as FFPE/degraded samples and ultra-low input samples. The SeqLL tSMS platform is the first to offer Direct RNA Sequencing (DRS™) capabilities.
“We believe that our Early Access Program will allow research partners to gain experience with the power of tSMS technology to discover what their current sequencing approaches are missing,” states Elizabeth Reczek, Ph.D., CEO at SeqLL. “Our vision is to bring this proprietary, amplification-free technology to market in mid-2017, backed by a commitment to unsurpassed customer support and uncompromising quality.”
About the Early Access Program
SeqLL’s Early Access Program will run from October 2016 through early 2017. SeqLL is now seeking collaborators to field test beta versions of the system. Data generated from the Early Access Program will be used to optimize the ease of use and training materials in support of the mid-2017 commercial launch of the tSMS Benchtop System. Priority will be given to collaborators with a near term research project that would benefit from the unique capabilities of the tSMS platform to generate superior and/or complimentary results to other sequencing approaches.
SeqLL’s exclusive true Single Molecule Sequencing platform enables direct parallel sequencing of millions of individual molecules. This novel amplification-free technology precisely reflects sample composition without bias and loss of diversity via a simple, integrated workflow and benchtop instrument design. In contrast with other technologies, sample preparation is minimized to as little as 3 steps. tSMS can deliver linear quantification over a 5-log range and sensitivity to 1.3-1.5-fold differences in expression levels. It is ideal for fragment sizes as low as 50 base pairs and can yield valuable data from even picogram-level input.
Located in Woburn, MA, SeqLL, LLC was founded in 2013 to bring a new breed of next generation sequencing technology, true Single Molecule Sequencing (tSMS), to the research and healthcare communities. SeqLL currently offers its amplification-free transcriptome profiling, specialty DNA analysis and bioinformatics on a service basis.
For more information, please visit www.SeqLL.com.
Source – BusinessWire